Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astra USA
Patients are randomized to receive oral hydration versus intravenous hydration therapy during concomitant intermittent intravenous Foscavir therapy for treatment of cytomegalovirus (CMV) retinitis. Treatment continues during 2 or 3 weeks of induction Foscavir therapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
Documented HIV infection.
Recent diagnosis of CMV retinitis, by ophthalmoscopic appearance, that requires induction therapy.
No corneal, lens, or vitreous opacification that precludes examination of the fundi.
No evidence of other end organ CMV infection.
No evidence of tuberculous, diabetic, or hypertensive retinopathy.
You may not be if
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Clinically significant cardiac, pulmonary, neurologic, gastrointestinal or renal impairment that would prevent adequate voluntary oral hydration (e.g., intubation, coma, status post-gastrectomy, colon resection, gastrointestinal tumors, malabsorption, chronic diarrhea) OR with which hydration would be hazardous (e.g., congestive heart failure).
Known allergy to foscarnet or related compounds.
Considered noncompliant or unreliable for study participation.
